Recombinant Interferon-Beta1a Use in Six Patients with Myeloproliferative Neoplasms: A First Impression

Objective: Assess the safety and efficacy of recombinant interferon-beta1a (rIFN-β1a) in myeloproliferative neoplasm (MPN) patients transitioning from pegylated interferon-alpha2 (peg-IFN-α2). Method: Retrospective review of six MPN patients switching to rIFN-β1a (44 mcg weekly). Results: All patients reported myalgia. No other adverse events or treatment discontinuations. Reduced JAK2V617F allele burden in three patients. Conclusion: rIFN-β1a demonstrated manageable safety in MPN patients, with potential efficacy. Larger studies are needed.